UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 9, 2017 (October 31, 2016)
ARALEZ PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
British Columbia, Canada | | 001-37691 | | 98-1283375 |
(State or other jurisdiction of
incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
7100 West Credit Avenue, Suite 101, Mississauga,
Ontario, Canada | | L5N 0E4 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (905) 876-1118
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Explanatory Note
The Registrant hereby amends its Current Report on Form 8-K previously filed on November 4, 2016 (as amended on January 13, 2017, the “Amended 8-K”) solely for the purpose of amending Item 9.01(d) of the Amended 8-K to update and replace the Consent of KPMG LLP included in Exhibit 23.1 to the Amended 8-K. Other than as set forth in this Explanatory Note, this Form 8-K/A does not amend any other items in the Amended 8-K or include any other modifications to the exhibits included as part of the Amended 8-K.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
EXHIBIT
NO. | | DESCRIPTION |
| | |
23.1 | | Consent of KPMG LLP |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 9, 2017 | ARALEZ PHARMACEUTICALS INC. |
| | |
| By: | /s/ Eric L. Trachtenberg |
| | Eric L. Trachtenberg |
| | General Counsel, Chief Compliance Officer and Corporate Secretary |
4
